Today: 25 January 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

CSL Limited (ASX:CSL) Share Price, Buyback and 2026 Outlook: Latest News and Forecasts as at 5 December 2025

CSL Limited (ASX:CSL) Share Price, Buyback and 2026 Outlook: Latest News and Forecasts as at 5 December 2025

CSL Limited’s share price is still nursing some heavy bruises, but under the surface the story in December 2025 is more “complex reboot” than simple “fallen giant”. On 5 December 2025, the ASX healthcare heavyweight is trading near multi‑year lows after a brutal few months of restructuring, a guidance cut and a delayed vaccines spin‑off. At the same time, CSL…
5 December 2025
····
BHP Group (ASX:BHP, NYSE:BHP) Hits 52‑Week High on 5 December 2025 – What’s Next for the Mining Giant’s Stock?

BHP Group (ASX:BHP, NYSE:BHP) Hits 52‑Week High on 5 December 2025 – What’s Next for the Mining Giant’s Stock?

BHP Group Ltd has just moved back into the market’s spotlight. On 5 December 2025, its New York–listed ADRs (NYSE:BHP) hit a new 52‑week high of US$58.92, extending a roughly 13% gain over the past year and nudging above the previous range top. Investing.com India On the Australian market, ASX:BHP closed at about A$44.38 on 5 December, easing slightly after…
5 December 2025
····
GE Vernova (GEV) Stock on December 4, 2025: Romania Wind Deal, R&D Surge and Investor Day Risks

GE Vernova (GEV) Stock on December 4, 2025: Romania Wind Deal, R&D Surge and Investor Day Risks

GE Vernova Inc. (NYSE: GEV) continues to be one of 2025’s standout industrial names. By the close on December 4, 2025, the stock was trading around $635 per share, up roughly 5–6% intraday, with a market cap near $163 billion and heavy volume of more than 2.4 million shares. After a blockbuster rally of roughly 75–85% year to date, GE…
4 December 2025
····
FuelCell Energy (FCEL) Stock on December 4, 2025: Earnings Date Set, EXIM Loan, and AI Data Center Pivot Shape the 2026 Outlook

FuelCell Energy (FCEL) Stock on December 4, 2025: Earnings Date Set, EXIM Loan, and AI Data Center Pivot Shape the 2026 Outlook

FuelCell Energy, Inc. (NASDAQ: FCEL) is back on traders’ radar in early December 2025. The hydrogen fuel‑cell specialist has set a firm date for its fourth‑quarter and full‑year 2025 earnings release, fresh financing has landed for a major South Korean project, and the stock has just pushed above its 200‑day moving average — all while Wall Street still labels the…
4 December 2025
···
Pattern Group Stock (NASDAQ: PTRN) Tanks After Bear Cave Short Report — Latest Price, News and 2026 Forecasts

Pattern Group Stock (NASDAQ: PTRN) Tanks After Bear Cave Short Report — Latest Price, News and 2026 Forecasts

Pattern Group Inc. (NASDAQ: PTRN), the freshly listed ecommerce and AI “accelerator” for consumer brands, just graduated from quiet new listing to full‑blown battleground stock. On Thursday, December 4, 2025, shares slid sharply after short‑selling newsletter The Bear Cave published a critical report questioning Pattern Group’s business model, reliance on Amazon and current valuation. Benzinga The selloff comes barely three…
4 December 2025
···
EQB Inc. (TSX: EQB) Soars on PC Financial Deal as 2025 Earnings Disappoint – Full Stock Analysis for December 4, 2025

EQB Inc. (TSX: EQB) Soars on PC Financial Deal as 2025 Earnings Disappoint – Full Stock Analysis for December 4, 2025

TORONTO – December 4, 2025 – Shares of EQB Inc. (TSX: EQB) ripped higher today after the digital lender unveiled a transformative deal to acquire PC Financial from Loblaw alongside a mixed fourth‑quarter and fiscal 2025 earnings report. The stock traded around C$97.71, up roughly 12.5% intraday, its sharpest move in months, pushing EQB’s market cap to about C$3.3 billion.…
4 December 2025
····
Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon (PLRZ) Stock Doubles on Naloxone Hydrogel Breakthrough and PL‑14 Manufacturing Milestone – What Investors Need to Know on December 4, 2025

Polyrizon Ltd. (NASDAQ: PLRZ) has exploded into the spotlight after a two‑day run that has turned an obscure micro‑cap biotech into one of the most talked‑about healthcare stocks on the Nasdaq. By early afternoon on December 4, 2025, Polyrizon shares were trading around $13–15, nearly doubling from Wednesday’s close at $7.09, with intraday highs reported above $18 and gains briefly…
4 December 2025
····
Regencell Bioscience (RGC) Stock Jumps Over 20% on December 4, 2025 as DOJ Probe and Going‑Concern Warning Shadow 2025’s Wildest Rally

Regencell Bioscience (RGC) Stock Jumps Over 20% on December 4, 2025 as DOJ Probe and Going‑Concern Warning Shadow 2025’s Wildest Rally

Regencell Bioscience Holdings Limited (NASDAQ: RGC) is back on traders’ radar. On Thursday, December 4, 2025, RGC shares surged more than 20% intraday, trading in the mid‑teens after yet another volatile session in what has arguably been 2025’s most extreme stock story. Intraday data from several market trackers showed the stock changing hands around $16–17, up roughly 24–31% on the…
4 December 2025
SAIC Stock Soars 16% After Q3 2026 Earnings Beat and Pentagon Contract Win: Is the Rally Just Getting Started?

SAIC Stock Soars 16% After Q3 2026 Earnings Beat and Pentagon Contract Win: Is the Rally Just Getting Started?

Science Applications International Corporation (NASDAQ: SAIC) is back on traders’ radar in a big way. On December 4, 2025, the stock surged roughly 16% after the company reported better‑than‑expected fiscal Q3 2026 earnings, raised full‑year guidance and highlighted a string of major U.S. government contract wins. Stock Titan Even after this sharp move, Wall Street remains broadly cautious with a…
4 December 2025
····
Intuitive Machines (LUNR) Stock on December 4, 2025: Price Action, NASA Catalysts and 2026 Forecasts

Intuitive Machines (LUNR) Stock on December 4, 2025: Price Action, NASA Catalysts and 2026 Forecasts

As of December 4, 2025, Intuitive Machines, Inc. (NASDAQ: LUNR) is back in the spotlight. The space-infrastructure company behind the Nova‑C lunar lander and NASA’s Commercial Lunar Payload Services (CLPS) missions is trading around $11.49 per share, up roughly 12–13% on the day, with intraday volume over 5.4 million shares – well above normal levels. StockInvest The move extends a…
4 December 2025
···
Rocket Lab Stock (RKLB) Soars on Record Launch Cadence, $1.1 Billion Backlog and 2026 Neutron Bets – December 4, 2025 Update

Rocket Lab Stock (RKLB) Soars on Record Launch Cadence, $1.1 Billion Backlog and 2026 Neutron Bets – December 4, 2025 Update

Ticker: Rocket Lab Corporation (NASDAQ: RKLB) – Space launch and space systems Where Rocket Lab Stock Stands Today As of early afternoon on December 4, 2025, Rocket Lab shares trade around $48.80, up roughly 9% on the day and sitting firmly near the upper end of their recent range. The stock has a 52‑week range of $14.71 to $73.97 and…
4 December 2025
····
Luminar Technologies (LAZR) Stock Jumps on Buyout Hopes Amid Volvo Split and Debt Crunch

Luminar Technologies (LAZR) Stock Jumps on Buyout Hopes Amid Volvo Split and Debt Crunch

As of December 4, 2025, Luminar Technologies, Inc. (NASDAQ: LAZR) is trading more like a distressed option on the future of lidar than a normal growth stock. The share price has bounced sharply intraday — up nearly 25% around midday Thursday to about $1.10–$1.14 — but that move comes after a brutal collapse from a 52‑week high of $10.40 and…
4 December 2025
····
1 … 635 636 637 638 639 … 720

Stock Market Today

  • Novo Nordisk Shares Seen as Undervalued Despite 27.8% Drop Over Past Year
    January 25, 2026, 10:48 AM EST. Novo Nordisk's (NYSE:NVO) stock has declined 27.8% over the past year but gained 18.8% in the last month. Despite this, a discounted cash flow (DCF) model estimates an intrinsic value of $149.81 per share, suggesting shares trade at a 58.4% discount to fair value. Novo Nordisk scored 5 out of 6 on Simply Wall St's valuation framework, indicating undervaluation on most metrics. Analysts forecast free cash flow growth through 2030, supporting bullish long-term prospects. The recent mixed return profile and ongoing interest as a leading pharma firm frame current investor debates on valuation and risks. Novo Nordisk remains a key biotech name under close watch for potential upside against recent price weakness.
Go toTop